Company news: Physicians Interactive, Boehringer Ingelheim

Share this article:

Physicians Interactive named Dr. Gautam Gulati Chief Medical Officer and SVP of product management. Gulati will be overseeing product development lines. He was previously SVP at Digitas Health. Joe Caso was named EVP of new business. Caso's marketing focus will include marketing strategies that will retain prescription momentum for drugs that are aging out of their patent protection. Caso has worked with King Pharmaceuticals, Pfizer and Schering-Plough.

An anonymous physician complaint prompted the UK Prescription Medicines Code of Practice Authority to come down on German drug maker Boehringer Ingelheim, InPharm reported Thursday. The government agency found that BI's professional website for the blood thinner Pradaxa did not clearly indicate where users could find prescribing information. Instead, the site requires users to click the clinical indication, a location the doctor said was buried in promotional information. PMPCA agreed. 
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...